Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in either the EGFR TK domain or the KRAS gene can lead to lung cancer pathogenesis.
|
15741570 |
2005 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There's a need for developing target therapies for KRAS mutant lung cancer and other tumors.
|
26840022 |
2016 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A major locus affecting inherited predisposition to lung cancer in mice has been mapped on chromosome 6, near the Kras2 gene.
|
8967717 |
1996 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It was applied to analyze mutations in codon 12 of the K-ras gene in 43 tissue sites microdissected from paraffin-embedded sections obtained from 8 archival cases of lung cancer, all previously shown to have codon 12 K-ras mutations by direct sequencing.
|
9177704 |
1997 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognostic and therapeutic implications of the spectrum of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene substitutions in lung cancer remain poorly understood.
|
23526491 |
2013 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent advances in the characterization of the lung cancer genome have suggested that KRAS may frequently be amplified, although little is known regarding the significance of this finding.
|
19762526 |
2009 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.
|
20848283 |
2011 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that REG4 plays an important role in KRAS-driven lung cancer pathogenesis and is a novel biomarker of lung adenocarcinoma subtype.
|
31428934 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review summarizes the progress in personalized care of lung cancer by reviewing the literature on EGFR, ALK and KRAS molecular alterations, currently used in clinical practice, to direct the decision making process for lung cancer therapy.
|
25563851 |
2014 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with stage I-III KRAS-mutant lung cancer who completed curative therapy were enrolled.
|
25044103 |
2014 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.
|
23917487 |
2013 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using an inducible LSL-KRAS(G12D) model of lung cancer in vivo, we show a transient upregulation of Notch pathway activity in early tumor precursor lesions.
|
21994468 |
2011 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
|
27121230 |
2016 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that long-term supplementation with the antioxidants N-acetylcysteine and vitamin E promotes KRAS-driven lung cancer metastasis.
|
31257027 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi-ERBB inhibitors in rationally designed treatment strategies.
|
29925636 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fifty seven patients with clinical diagnosis of lung cancer and detectable KRAS mutations in pre-surgery EBC-DNA were qualified for surgical treatment.
|
22795503 |
2012 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Together, our results suggest that mutant KRAS promotes RAD51 expression to enhance DNA damage repair and lung cancer cell survival, suggesting that RAD51 may be an effective therapeutic target to overcome chemo/radioresistance in KRAS mutant cancers.[BMB Reports 2019; 52(2): 151-156].
|
30638176 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, we designed a meta-analysis to evaluate the diagnostic value and prognostic significance of a KRAS proto-oncogene, GTPase (KRAS) mutation for lung cancer patients.
|
28415658 |
2017 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The successful enrollment of 30 patients with tumors with KRAS mutant lung adenocarcinoma over 15 months at a single site demonstrates that drug trials directed at a KRAS-specific genotype in lung cancer are feasible.
|
21847063 |
2011 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therapeutically, KRAS mutation testing has maximum utility in stratifying metastatic colorectal carcinoma and lung cancer patients for treatment with targeted therapy.
|
25487540 |
2015 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This work sheds light on the ability of RASto activate PI3K through direct interaction, indicating that input is also required from a receptor tyrosinekinase, IGF1R in the case of KRAS -mutant lung cancer.
|
23454899 |
2013 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).
|
25634006 |
2015 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ).
|
28376145 |
2017 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the inhibitory effect of miR-200c-dependent KRAS silencing on proliferation and cell cycle was demonstrated in different breast and lung cancer cell lines.
|
24368337 |
2014 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells.
|
28443025 |
2017 |